BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 10698713)

  • 1. Analysis of the cellular functions of PTEN using catalytic domain and C-terminal mutations: differential effects of C-terminal deletion on signalling pathways downstream of phosphoinositide 3-kinase.
    Leslie NR; Gray A; Pass I; Orchiston EA; Downes CP
    Biochem J; 2000 Mar; 346 Pt 3(Pt 3):827-33. PubMed ID: 10698713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting mutants of PTEN reveal distinct subsets of tumour suppressor functions.
    Leslie NR; Bennett D; Gray A; Pass I; Hoang-Xuan K; Downes CP
    Biochem J; 2001 Jul; 357(Pt 2):427-35. PubMed ID: 11439092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif.
    Walker SM; Leslie NR; Perera NM; Batty IH; Downes CP
    Biochem J; 2004 Apr; 379(Pt 2):301-7. PubMed ID: 14711368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antagonism of PI 3-kinase-dependent signalling pathways by the tumour suppressor protein, PTEN.
    Downes CP; Bennett D; McConnachie G; Leslie NR; Pass I; MacPhee C; Patel L; Gray A
    Biochem Soc Trans; 2001 Nov; 29(Pt 6):846-51. PubMed ID: 11709086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The PTEN lipid phosphatase domain is not required to inhibit invasion of glioma cells.
    Maier D; Jones G; Li X; Schönthal AH; Gratzl O; Van Meir EG; Merlo A
    Cancer Res; 1999 Nov; 59(21):5479-82. PubMed ID: 10554022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of synovial fibroblasts in rheumatoid arthritis: lack of Expression of the tumour suppressor PTEN at sites of invasive growth and destruction.
    Pap T; Franz JK; Hummel KM; Jeisy E; Gay R; Gay S
    Arthritis Res; 2000; 2(1):59-64. PubMed ID: 11219390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC.
    Haas-Kogan D; Shalev N; Wong M; Mills G; Yount G; Stokoe D
    Curr Biol; 1998 Oct; 8(21):1195-8. PubMed ID: 9799739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The tumor suppressor PTEN positively regulates macroautophagy by inhibiting the phosphatidylinositol 3-kinase/protein kinase B pathway.
    Arico S; Petiot A; Bauvy C; Dubbelhuis PF; Meijer AJ; Codogno P; Ogier-Denis E
    J Biol Chem; 2001 Sep; 276(38):35243-6. PubMed ID: 11477064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity.
    Koul D; Jasser SA; Lu Y; Davies MA; Shen R; Shi Y; Mills GB; Yung WK
    Oncogene; 2002 Apr; 21(15):2357-64. PubMed ID: 11948419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor.
    Georgescu MM; Kirsch KH; Kaloudis P; Yang H; Pavletich NP; Hanafusa H
    Cancer Res; 2000 Dec; 60(24):7033-8. PubMed ID: 11156408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein.
    Paramio JM; Navarro M; Segrelles C; Gómez-Casero E; Jorcano JL
    Oncogene; 1999 Dec; 18(52):7462-8. PubMed ID: 10602505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute regulation of the tumour suppressor phosphatase, PTEN, by anionic lipids and reactive oxygen species.
    Downes CP; Walker S; McConnachie G; Lindsay Y; Batty IH; Leslie NR
    Biochem Soc Trans; 2004 Apr; 32(Pt 2):338-42. PubMed ID: 15046604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A role for the actin cytoskeleton in the hormonal and growth-factor-mediated activation of protein kinase B.
    Peyrollier K; Hajduch E; Gray A; Litherland GJ; Prescott AR; Leslie NR; Hundal HS
    Biochem J; 2000 Dec; 352 Pt 3(Pt 3):617-22. PubMed ID: 11104665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase.
    Mahimainathan L; Choudhury GG
    J Biol Chem; 2004 Apr; 279(15):15258-68. PubMed ID: 14718524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTEN: The down side of PI 3-kinase signalling.
    Leslie NR; Downes CP
    Cell Signal; 2002 Apr; 14(4):285-95. PubMed ID: 11858936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis.
    Wick W; Furnari FB; Naumann U; Cavenee WK; Weller M
    Oncogene; 1999 Jul; 18(27):3936-43. PubMed ID: 10435616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.
    Han SY; Kato H; Kato S; Suzuki T; Shibata H; Ishii S; Shiiba K; Matsuno S; Kanamaru R; Ishioka C
    Cancer Res; 2000 Jun; 60(12):3147-51. PubMed ID: 10866302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redox regulation of PI 3-kinase signalling via inactivation of PTEN.
    Leslie NR; Bennett D; Lindsay YE; Stewart H; Gray A; Downes CP
    EMBO J; 2003 Oct; 22(20):5501-10. PubMed ID: 14532122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTEN function: how normal cells control it and tumour cells lose it.
    Leslie NR; Downes CP
    Biochem J; 2004 Aug; 382(Pt 1):1-11. PubMed ID: 15193142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death.
    Weng LP; Smith WM; Dahia PL; Ziebold U; Gil E; Lees JA; Eng C
    Cancer Res; 1999 Nov; 59(22):5808-14. PubMed ID: 10582703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.